

PCT




WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification <sup>7</sup> : <b>C07D 401/04, C07B 53/00 // (C07D 401/04, 221:00, 211:00)</b></p>	<p><b>A1</b></p>	<p>(11) International Publication Number: <b>WO 00/31064</b> (43) International Publication Date: <b>2 June 2000 (02.06.00)</b></p>
<p>(21) International Application Number: <b>PCT/US99/26009</b> (22) International Filing Date: <b>18 November 1999 (18.11.99)</b> (30) Priority Data: <b>09/197,005</b>      <b>20 November 1998 (20.11.98)</b>      <b>US</b> (71) Applicant: <b>SCHERING CORPORATION [US/US]; 2000 Galloping Hill Road, Kenilworth, NJ 07033-0530 (US).</b> (72) Inventors: <b>KUO, Shen-Chun; 140 Glenwood Court, Union, NJ 07083 (US). BERNARD, Charles, F.; 4112 Yankee Drive, Agoura Hills, CA 91301 (US). CHEN, Frank, Xing; 12 Bradford Lane, Plainsboro, NJ 08536 (US). HOU, Donald; 13 Nassau Road, Verona, NJ 07044 (US). KIM-MEADE, Agnes, S.; 212 Second Street, Fanwood, NJ 07023 (US). WU, George, G.; 88 Vanderveer Drive, Basking Ridge, NJ 07920 (US).</b> (74) Agents: <b>MANN, Arthur et al.; Schering-Plough Corporation, Patent Dept., K-6-1 1990, 2000 Galloping Hill Road, Kenilworth, NJ 07033-0530 (US).</b></p>		<p>(81) Designated States: <b>AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MA, MD, MG, MK, MN, MX, NO, NZ, PL, PT, RO, RU, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UZ, VN, YU, ZA, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).</b>  <b>Published</b> <i>With international search report.</i></p>

(54) Title: ENANTIOSELECTIVE ALKYLATION OF TRICYCLIC COMPOUNDS



(57) Abstract

Disclosed is a process for preparing a compound of formula (I) wherein  $X^1$ ,  $X^2$ ,  $X^3$ ,  $X^4$  and  $X^5$  are independently selected from the group consisting of H, halo, alkyl, alkoxy, aryl, and aryloxy, and R is a protecting group, in which a compound having formula (II) wherein  $X^1$ ,  $X^2$ ,  $X^3$ ,  $X^4$  and  $X^5$  are as defined above, is treated with the following, in any sequence: (a) a non-nucleophilic strong base; (b) a chiral amino alcohol; and (c) a compound having formula (V) wherein L is a leaving group and R is as defined above. The compounds made by this process are useful intermediates for preparing compounds that are inhibitors of farnesyl protein transferase.

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

## ENANTIOSELECTIVE ALKYLATION OF TRICYCLIC COMPOUNDS

### BACKGROUND OF THE INVENTION

10

This invention provides a process for preparing intermediates useful in the preparation of tricyclic compounds known as inhibitors of farnesyl protein transferase. In particular, the compounds prepared by the process of this invention are useful as chiral intermediates in the preparation of chiral compounds that are FPT inhibitors  
15 such as those disclosed in PCT Publication No. WO97/23478, published July 3, 1997.


Over the last few decades a number of enantioselective carbon-carbon bond forming reactions have been developed that fall into two distinct groups - those that involve alkylations of a covalently bonded chiral precursor and those that use a non-covalently bonded chiral auxiliary. Examples of the former include Evan's  
20 oxazolidinone system, Meyer's oxazoline system and Enders' RAMP/SAMP systems. (See Evans, D. A., *et al.*, *Encyclopedia of Reagents for Organic Synthesis*; Wiley: Chichester, 1995, Vol. 1, p. 345; Gant, T. G.; Meyers, A.I. *Tetrahedron* **1994**, *50*, 2297; and Enders, D. *et al.*, *Liebigs Ann.* **1995**, 1127.) Examples of the latter, include alkylations of stabilized anions of ketones, imines, amino acid derived Schiff bases,  
25 N-alkyl carbamates and O-alkyl carbamates that are stabilized using non-covalently bonded chiral alkaloid bases or chiral lithium bases. (See, e.g., Hughes, D. L., *et al.*, *J. Org. Chem.* **1987**, *52*, 4745.; Sato, D. *et al.*, *Tetrahedron* **1997**, *53*, 7191; Koga, K. *Pure & Appl. Chem.* **1994**, *66*, 1487; Tomioka, K. *et al.*, *Chem. Pharm. Bull.* **1989**, *37*, 1120; O'Donnell, M. J., *et al.*, *Tetrahedron* **1994**, *50*, 4507; Weisenburger, G. A. *et al.*, *J. Am. Chem. Soc.* **1996**, *118*, 12218; Gallagher, D. J. *et al.*, *J. Am. Chem. Soc.* **1996**, *118*, 11391; and Hoppe, D. *et al.*, *Pure & Appl. Chem.* **1996**, *68*, 613.) These reactions are similar in that the anion that is generated and alkylated has an adjacent carbonyl-type stabilizing group such as a ketone, imine or hydrazone. There have been few examples of a non-carbonyl type group stabilized anion. Gawley reported  
30 that an  $\alpha$ -aminoorganolithium anion generated from a chiral stannane precursor is configurationally stable, and although alkylation with primary alkyl halides affords products with excellent enantioselectivity in certain cases, the fact that the chiral

- 5 stannane precursor must be resolved detracts from this procedure. (See Gawley, R. E., *et al*, *J. Org. Chem.* **1995**, *60*, 5763.) Noyori *et al.* reported that silylation and carboxylation of the anion of the ethyl benzene/(-)-sparteine complex proceeds in  $\approx 30\%$  enantiomeric excess (e.e.) with low yields and significant amounts of reaction on the aromatic nucleus was also observed. (See Nozaki, H.; Aratani, T.; Toraya, T.; Noyori, R. *Tetrahedron* **1971**, *27*, 905.) White *et al.* reported that methylation of a 2-methylpyridine/(-)-sparteine complex proceeds in 20% e.e. and 64% yield. (See Papasergio, R. I.; Skelton, B. W.; Twiss, P.; White, A. H.; Raston, C. L. *J. Chem. Soc. Dalton Trans.* **1990**, 1161.) Hoppe *et al.* reported that acylation of an indenine system (allylic anion) proceeded in  $>95\%$  ee with 52-79% yields. (See Hoppe, I. *et al*, *Angew. Chem. Int. Ed. Engl.* **1995**, *34*, 2158.)

We have now discovered a process for the enantioselective alkylation of non-ketone/amide/carbamate/imine benzyl type methylene compounds utilizing a chiral amino alcohol as a chiral ligand that results in high e.e. and high yield of intermediates useful for preparing the chiral FPT inhibitors discussed above.

### SUMMARY OF THE INVENTION


This invention provides a process for preparing a compound of the formula:



25

wherein X<sup>1</sup>, X<sup>2</sup>, X<sup>3</sup>, X<sup>4</sup>, and X<sup>5</sup> are independently selected from the group consisting of H, halo, alkyl, alkoxy, aryl, and aryloxy, and R is a protecting group, said process comprising:

treating a compound having the formula




5

wherein  $X^1$ ,  $X^2$ ,  $X^3$ ,  $X^4$ , and  $X^5$  are as defined above, with the following, in any sequence:


- (a) a non-nucleophilic strong base;  
 (b) a chiral amino alcohol; and  
 (c) a compound having the formula

10



wherein L is a leaving group and R is as defined above.

Also claimed herein is a process for preparing a compound having the formula




15

wherein  $X^1$ ,  $X^2$ ,  $X^3$ ,  $X^4$ , and  $X^5$  are independently selected from the group consisting of H, halo, alkyl, alkoxy, aryl, and aryloxy, and R is a protecting group, said process comprising:


- (a) reacting a compound having the formula

20



wherein  $X^1$ ,  $X^2$ ,  $X^3$ ,  $X^4$ , and  $X^5$  are as defined above, with a non-nucleophilic strong base in the presence of a chiral amino alcohol to form a complex; and

(b) reacting the complex formed in step (a) with a compound having the formula



wherein L is a leaving group and R is as defined above.

### DETAILED DESCRIPTION

As used herein, the term “alkyl” means straight or branched hydrocarbon chain groups having 1 to 6 carbon atoms.

“Halo” means fluorine, chlorine, bromine or iodine radicals.

“Alkoxy” refers to groups having the formula -OR, wherein R is alkyl.

“Aryl” refers to a carbocyclic group having at least one aromatic ring.


“Aryloxy” refers to a group having the formula -OR, wherein R is aryl.

“e.e.” represents the percentage obtained by subtracting the amount of the S-enantiomer from the R-enantiomer, and dividing by the sum of the amount of R-enantiomer and S-enantiomer :

e.e. % =  $100 \times (R\text{-enantiomer} - S\text{-enantiomer}) / (R\text{-enantiomer} + S\text{-enantiomer})$ .

The following abbreviations are used herein: “Boc” refers to tert-butoxy carbonyl; “LDA” refers to lithium diisopropylamide; “THF” refers to tetrahydrofuran; and “Ph” refers to a phenyl group.

5 The compounds prepared by the process disclosed above are useful as intermediates for preparing chiral compounds that are FPT inhibitors, such as those disclosed in PCT Publication No. WO97/23478, published July 3, 1997. Such compounds may be prepared by deprotecting the compound of formula (I), i.e., removing the R group by treatment with acid (e.g.,  $H_2SO_4$ ) to form the free amine, or  
 10 optionally reacting the free amine with a suitable acid (e.g., N-acetyl-L-phenylalanine) to form a stable salt, and acylating the free base or the salt with the desired acyl group to form the desired FPT inhibitor. The compounds prepared by the process of the present invention are particularly useful for preparing the following compound:







15

Preferably,  $X^1$ ,  $X^2$ ,  $X^3$ ,  $X^4$ , and  $X^5$  are selected from H or halo. More preferably,  $X^2$  and  $X^4$  are H, and  $X^1$ ,  $X^3$  and  $X^5$  are halo. Halo is most preferably Cl or Br. Most preferably,  $X^1$  is Br,  $X^2$  is H,  $X^3$  is Cl,  $X^4$  is H, and  $X^5$  is Br.

Non-limiting examples of leaving groups, L, include sulfonates (e.g., mesylate, tosylate, closylate (para-chloro tosylate), and brosylate (para-bromo tosylate)), phosphates (e.g., alkyl phosphates, such as diethyl phosphate), benzoates, and halo. Preferably, the leaving group, L, is a sulfonate, more preferably, mesylate or tosylate.


The protecting group may be any group suitable for protecting the nitrogen atom of the piperidine ring. Non-limiting examples of protecting groups include  
 25 sulfonates, and acyl groups, e.g., tert-butoxycarbonyl (BOC),







- 5 Preferably, the protecting group is an acyl group, more preferably, tert-




- Examples of suitable non-nucleophilic strong bases include, but are not limited to, lithium diisopropylamide (LDA), lithium 2,2,6,6-tetramethylpiperidine, 1-lithium 4-methylpiperazide, 1,4-dilithium piperazide, lithium bis(trimethylsilyl) amide, sodium bis(trimethylsilyl)amide, potassium bis(trimethylsilyl)amide, isopropyl magnesium chloride, phenyl magnesium chloride, lithium diethylamide, and potassium *tert*-butoxide. Preferably, the non-nucleophilic strong base is LDA.
- 10

Non-limiting examples of chiral amino alcohols include quinine and quinine derivatives, 1,2- and 1,3-aminoalcohol derivatives, and quinoline alcohol derivatives.


- 15 Preferably, the chiral amino alcohol is a compound

(i) having the formula




- wherein the dotted line represents an optional second bond and wherein R<sup>1</sup> is selected from alkoxy, aryloxy, or NR<sup>A</sup>R<sup>B</sup>, wherein R<sup>A</sup> and R<sup>B</sup> are selected from alkyl or aryl, R<sup>1</sup> being optionally substituted by one or more alkoxy groups, or
- 20

(ii) having the formula




- wherein R<sup>2</sup> is a phenyl group optionally substituted by 1 to 5 substituents independently selected from the group consisting of alkyl and alkoxy.
- 25


- 5 The chiral amino alcohol of formula (III), above, is quinine, or a quinine derivative. Non-limiting examples of chiral amino alcohols of formula (III) include






Quinine




Hydroquinine




(-)-Cinchonidine




and



- 10 Preferably, R<sup>1</sup> in formula (III) is alkoxy. The chiral amino alcohol of formula (III) is most preferably selected from quinine, hydroquinine,





and




Quinine is especially preferred.


- 5        The chiral amino alcohol of formula (IV) is a derivative of norephedrine. Preferably,  $R^2$  is phenyl substituted with 1-3 alkoxy substituents. Preferably, the alkoxy substituents are methoxy or ethoxy, with methoxy being particularly preferred. Non-limiting examples of chiral amino alcohols of formula (IV) include:




and



- 10      The chiral amino alcohol of formula (IV) is most preferably



- It is believed that the process claimed herein proceeds according to the following mechanism: The base accepts a proton from the tricyclic compound of formula (II), forming an anion:
- 15



5

The tricyclic anion subsequently forms a complex with the chiral amino alcohol and the base. The tricyclic anion of the complex reacts with the piperidine compound of formula (V), displacing the leaving group L, thereby forming the desired compound of formula (I).

The process of our invention is preferably carried out in an organic solvent. Suitable organic solvents, include, but are not limited to non-protic organic solvents, e.g., toluene, benzene, cyclohexane, tetrahydrofuran, anisole, chlorobenzene, and mixtures thereof. Toluene is a particularly preferred solvent.

The process is preferably carried out at a temperature range of from -20° C to +60° C, more preferably, at a temperature range of from -10° C to +40° C, most preferably, at a temperature range of from 0° C to +25° C.

The amount of non-nucleophilic strong base used preferably ranges from 3.0 to 5.0 equivalents, more preferably 3.0 to 4.0 equivalents, most preferably 3.0 to 3.6 equivalents.

The amount of the chiral amino alcohol used preferably ranges from 1.0 to 2.0 equivalents, more preferably 1.0 to 1.5 equivalents, most preferably 1.0 to 1.3 equivalents.

The amount of the piperidine compound of formula (V) used preferably ranges from 1.0 to 2.0 equivalents, more preferably 1.0 to 1.5 equivalents, most preferably 1.0 to 1.3 equivalents.

As noted above, the tricyclic starting compound may be treated with the non-nucleophilic strong base, the chiral amino alcohol, or the piperidine compound of formula (V) in any order, including mixtures of these reagents.

The process of our invention is preferably carried out such that at least one of the treatments with the non-nucleophilic strong base, the chiral amino alcohol, or the piperidine compound of formula (V) occurs in the presence of water or a C<sub>1</sub> - C<sub>3</sub> alcohol (e.g., methanol), most preferably, water. The amount of water or C<sub>1</sub> - C<sub>3</sub>

30

- 5 alcohol used preferably ranges from 0.1 to 3.0 equivalents, more preferably 0.8 to 1.2 equivalents, most preferably 0.9 to 1.1 equivalents. The water or C<sub>1</sub> - C<sub>3</sub> alcohol may be added to the tricyclic starting compound prior to, or simultaneously with, the addition of the base, the chiral amino alcohol, or the piperidine compound, or it may be added after any or all of these compounds are brought into contact with the
- 10 tricyclic starting compound.


In a particularly preferred embodiment:

- (a) 1.2 to 1.4 eq. of the non-nucleophilic strong base, preferably about 1.3 eq., are added to a solution containing:
- (i) the compound of formula (II),
- 15 (ii) 1.1 to 1.3 eq. of the compound of formula (V), preferably about 1.2 eq., and
- (iii) 1.2 to 1.4 eq. of the chiral amino alcohol, preferably about 1.3 eq., while maintaining the temperature at 10° C to 30° C, preferably 15° C to 25° C;
- (b) the mixture from step (a) is cooled to 0° C to 10° C, preferably 0° C
- 20 to 5° C, and 0.8 to 1.2 eq. of water, preferably about 1.0 eq. are added;
- (c) an additional 0.9 to 1.1 eq. of the non-nucleophilic strong base, preferably about 1.0 eq. are added to the mixture from step (b) while maintaining the temperature at 0° C to 10° C, preferably 0° C to 8° C; and
- (d) the temperature of the mixture from step (c) is raised to 14° C to
- 25 18° C, and an additional 1.1 to 1.3 eq. of the non-nucleophilic strong base, preferably about 1.2 eq. are added while maintaining the temperature at 14° C to 18° C.

The process of our invention is economical, because the chiral amino alcohol can be recovered and recycled for further use. For example, after the reaction is judged to be complete by HPLC, the reaction mixture can be quenched by adding

30 water, and stirred at a temperature of 0° C to 5° C to precipitate the chiral amino alcohol, which can be recovered by filtration.


The tricyclic starting compound of our process may be prepared by reducing a corresponding tricyclic ketone as depicted below:



5

The reduction of the tricyclic ketone may be carried out by methods well known in the art. Preferably, the reduction is carried out by treating the tricyclic ketone with Zn and 2 equivalents of trifluoroacetic acid in a 2:1 mixture of tetrahydrofuran / acetic anhydride. The tricyclic ketone may be prepared according to methods known in the

10 art, e.g., the methods described in PCT Publication Nos. WO97/23478, published July 3, 1997, WO96/31478, published October 10, 1996, WO96/30363, published October 3, 1996, and WO95/10516, published April 20, 1995. Alternatively, the tricyclic ketone may be prepared according to the following scheme:




5

As shown in the scheme above, the pyridine compound **1** is reacted with aniline in the presence of a palladium catalyst, e.g.,  $\text{Pd}(\text{OAc})_2$  or  $\text{PdCl}_2$ , carbon monoxide, a base, e.g., 1,8-diazabicyclo-[5.4.0]undec-7-ene ("DBU") or diisopropylethylamine, and an ether selected from ethylene glycol dimethyl ether, 2-methoxyethyl ether, and triethylene glycol dimethyl ether, to form amide compound **2**. The reaction to form amide compound **2** is preferably carried out at a temperature of about  $45^\circ\text{C}$  to  $90^\circ\text{C}$ , and a pressure of about 40 to 100 psi, in a suitable solvent, e.g., toluene or chlorobenzene. Amide compound **2** is reacted with an iodo-substituted compound **3**

- 5 in the presence of a strong base, e.g., lithium diisopropylamide, in a suitable solvent, e.g., THF, to form compound 4. Compound 4 is reacted with  $\text{CH}_3\text{I}$  and a base, e.g., NaH to form methylated compound 5. Compound 5 is cyclized to form the desired ketone by reaction with a Grignard reagent, e.g., 2-methoxyphenylmagnesium bromide.
- 10 Alternatively, the tricyclic ketone may be prepared according to the following scheme:






5

As shown in the scheme above, amide compound **2** is reacted with compound **6** in the presence of a strong base, e.g., lithium diisopropylamide, in a suitable solvent, e.g., THF to form compound **7**. Compound **7** is cyclized by treating it with a dehydrating agent and a super acid, e.g., P<sub>2</sub>O<sub>5</sub>/CF<sub>3</sub>SO<sub>3</sub>H or a dehydrating agent and a Lewis acid ,

10

- 5 e.g.,  $\text{PCl}_5/\text{AlCl}_3$  or  $\text{POCl}_3/\text{ZnCl}_2$ , and hydrolyzing the reaction product 8 to form the desired tricyclic ketone.

The norephedrine derivatives used in our process may be prepared by a one pot, two step process according to the following scheme:



10

As shown in the scheme above, (1R, 2S)-(-)- norephedrine is reacted with an optionally substituted benzaldehyde by refluxing in ethanol, and reducing the product of that reaction with sodium borohydride at ambient temperature to produce the desired norephedrine derivative compound.


5       The quinine derivatives used in our process are either commercially available, or may be made from quinine or hydroquinine using methods known to those skilled in the art. (See, e.g., H. King, *J. Chem. Soc.* **1946**, 523-524; and A. Renfrew, *et al*, *J. Am. Chem. Soc.* **1943**, 65, 2309-2310.)

10       The following examples illustrate the foregoing invention, although such examples should not be construed as limiting the scope of the invention. Alternative reagents and analogous processes within the scope of the invention will be apparent to those skilled in the art.

### PREPARATIVE EXAMPLE A

15

#### One-pot, two step preparation of the Trimethoxybenzyl-Norephedrine Ligand



20       (1R,2S) - (-) - Norephedrine (100 g) and 3,4,5-Trimethoxybenzaldehyde (143 g) are dissolved in ethanol (1 L) and brought to a gentle reflux for 4 to 5 hours (average time required for completion). The reaction mixture is then cooled down in an ice-water bath, and sodium borohydride (37 g) is added portionwise. Reduction

5 occurs overnight at room temperature. Once reduction is complete, the excess sodium borohydride is destroyed by adding water (25 mL). The organic solvent (ethanol) is then removed using a rotavap, and the product is extracted with ethyl acetate. Ethyl acetate is removed, using a rotovap, leaving behind trimethoxybenzyl-norephedrine as a colorless oil.

10


Further purification is achieved by dissolving the trimethoxybenzyl-norephedrine oil in methanol (400 mL) and slowly adding aqueous hydrobromic acid 48% w/w (73 mL). A white solid precipitates which is filtered after 1 hour of stirring at room temperature. The ligand salt is recrystallized in a mixture of methanol/diethyl  
15 ether (12:1). The recrystallized salt is then freebased, using diluted aqueous sodium hydroxide, and extracted with toluene. The toluene is then removed with a rotovap, leaving behind trimethoxybenzyl-norephedrine (188 g) as a colorless oil.

<sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 7.33-7.24 (m, 7H); 6.55 (s, 2H); 4.80 (d, *J*=3.8 Hz, 1H); 3.86-3.82 (m, 9H); 3.00 (dq, *J*= 3.8 and 6.5 Hz, 1H); 1.39 (d, *J*= 6.5 Hz, 1H); 0.9 (d, *J*= 6.5 Hz, 3H)  
20

<sup>13</sup>C NMR (CDCl<sub>3</sub>): 154.3, 142.2, 138.2, 136.4, 129.1, 128.1, 127.1, 106.0, 74.4, 62.0, 59.1, 57.3, 52.7, 15.9.

### PREPARATIVE EXAMPLE B

25




To a mixture of the tricyclic ketone shown above (40 kg, 1 eq.), acetic anhydride (72 L, 7.8 eq.) in THF (140 L) at -25° C was added zinc dust (22.4 kg, 3.5  
30 eq.) and then dropwise trifluoroacetic acid (16.8 L, 2.2 eq.) over a 2 hour period at -25° C to -20° C. The mixture was slowly raised to room temperature over a period of 2 hours and kept at 18° C to 20° C over a period of 20 hours. Supercel (4 kg) and toluene (400 L) were added and the mixture was filtered. The extra zinc and inorganic residue were washed with toluene (80 L). The filtrate and wash were

5 combined, and washed with water (200 L), 10% NaOH (160 L x 2) and water (200 L). After separating the organic layer from the aqueous layer, the organic layer was concentrated to 120 L. 2-Butanol (320 L) was added to the mixture, which was then concentrated to 120 L under vacuum. Again, 160 L of 2-butanol was added and the mixture was heated to reflux for 1 hour. The mixture was cooled down to 0° C to 5°  
10 C and stirred for 4 hours. The solid was filtered and washed with 80 L of 2-butanol. The crystalline product was dried under vacuum at 70° C. The yield was 32.6 kg (82%). Mp.: 163-164° C. <sup>1</sup>H NMR (CDCl<sub>3</sub>): 8.38 (d, *J* = 2.0 Hz, 1H), 7.46 (d, *J* = 2.0 Hz, 1H), 7.44 (d, *J* = 2.0 Hz, 1H), 7.14 (d, *J* = 2.0 Hz, 1H), 4.54 (s, 2H), 3.10 - 3.20 (m, 4H). <sup>13</sup>C NMR (CDCl<sub>3</sub>): 154.1, 148.5, 143.9, 141.7, 137.2, 135.8, 133.9, 131.6,  
15 128.7, 125.5, 119.8, 41.7, 32.9, 32.8.

If necessary, the product can be further purified by recrystallization from 7 volumes of 2-butanol and 1.5 volumes of toluene in 94% yield.

### EXAMPLE 1

#### Chiral alkylation using a Norephedrine based ligand



25 The trimethoxybenzyl-norephedrine ligand from Preparative Example A (76.8 g), the tricyclic methylene substrate from Preparative Example B (50 g) and mesylated N-protected piperidine derivative (43.2 g) are dissolved in toluene to a total volume of 1 L. The reaction mixture is then cooled down between 0° and -5°C and lithium diisopropyl amide mono (tetrahydrofuran) solution (1.5 M in cyclohexane)  
30 ("LDA") (155 mL) is added, followed by the addition of water (2.1 mL). At this point, the temperature is maintained between 0° and -5°C and the remaining LDA 1.5 M (172 mL) is added slowly over 4 to 5 hours. Once the reaction is completed, 1N


- 5 hydrochloric acid (1.2 L) is added to precipitate out the chiral inducing ligand which is recovered by filtration and can be reused without any further purification. The aqueous layer is then separated from the organic layer (toluene) which contains the alkylated product (93-95% ee, > 95% solution yield).

10

**EXAMPLE 2**

Using the procedure of Example 1, and substituting lithium 2,2,6,6,-tetramethyl piperidide for LDA, obtain the alkylated product (81% ee).

15

**EXAMPLE 3**


- To a cooled (0 to 5°C) solution of the norephedrine derivative shown above (0.9 g) and the tricyclic compound (1.0 g) shown above dissolved in 40 mL of degassed toluene was added dropwise LDA 1.5 M (3.8 mL). The mixture is stirred at that temperature for 2 hours. A solution of the mesylated N-protected piperidine derivative shown above (1 g in 10 mL in toluene) is added to the reaction mixture. The reaction is allowed to return to ambient temperature. Monitor the reaction by HPLC to determine completion to obtain the alkylated product (57 % ee).

25

**EXAMPLE 4**

- Using the same procedure as Example 3, obtain the alkylated product (48% ee) by substituting the following norephedrine derivative for the norephedrine derivative used in Example 2:

30




5

**EXAMPLE 5**

Using the same procedure as Example 3, obtain the alkylated product (62% ee)  
10 by substituting 1,4- dilithium piperazide for LDA.

5

**EXAMPLE 6**Chiral alkylation using quinine

- 10 Mix the tricyclic compound (6.0 g) shown above and 4-mesyloxy-N-Boc-piperidine (5.0 g) in 150 mL toluene, heat to 40° C for 30 minutes to obtain a clear solution, and cool to ambient temperature. Add the solution to a reaction flask containing solid quinine (6.0 g). Add 1.3 eq. of a solution of lithium diisopropylamide mono(tetrahydrofuran) (1.5 M in cyclohexane) ("LDA solution")
- 15 slowly, while maintaining the temperature below 10° C, until the mixture turns red. Add H<sub>2</sub>O (1.0 eq.), stir for 10 minutes, and cool the reaction mixture below 5° C. Slowly add 1.0 eq. of the LDA solution, and warm the reaction mixture to 14°C to 18° C to obtain a clear solution. Add an additional 1.1 eq. of the LDA solution over a two hour period. Warm the resulting mixture to ambient temperature and stir for 18 hours.
- 20 Quench the reaction mixture with 90 mL of 10% H<sub>2</sub>SO<sub>4</sub>. Remove the bottom aqueous solution. Add 24 mL of 20% H<sub>2</sub>SO<sub>4</sub> to the toluene solution (organic top layer), heat to 85° C for 4 hours, and cool down to ambient temperature. Add 15 mL of



- 5 concentrated  $\text{NH}_4\text{OH}$  to the reaction mixture and remove the bottom aqueous solution. Reduce the toluene solution (organic top layer) by vacuum distillation to a volume of 48 mL. Add 120 mL ethanol, and reduce by vacuum distillation down to a volume of 48 mL. Add a solution of 3.0 grams N-acetyl-L-phenylalanine in 120 mL ethanol, and subject the mixture to vacuum distillation to reduce the volume down to 48 mL.
- 10 Stir at  $70^\circ\text{C}$  for 1 hour, and cool to ambient temperature. Filter and wash the solid with a 1:1 solution of ethyl alcohol and methyl-t-butyl ether. Dry in a vacuum oven at a temperature of  $55^\circ\text{C}$  for 18 hours to give 8.75 grams of the desired salt (80% molar yield, 96% purity, >98% e.e.).


$^1\text{H}$  NMR of salt ( $\text{CDCl}_3$ ): 8.45 (s, 1H), 7.58 (s, 1H), 7.52 (s, 1H), 7.20 (m, 6H), 15 6.33 (d,  $J=6\text{Hz}$ , 1H), 4.96 (d,  $J=9\text{Hz}$ , 1H), 4.52 (m, 1H), 3.55 (m, 1H), 3.12-3.24 (m, 5H), 3.0 (m, 1H), 2.84 (m, 1H), 2.58 (m, 2H), 2.34 (m, 1H), 2.00 (s, 3H), 1.82 (m, 1H), 1.62 (m, 2H), 1.42 (m, 1H).

$^1\text{H}$  NMR of free base ( $\text{CDCl}_3$ ): 8.45 (s, 1H), 7.52 (s, 1H), 7.48 (s, 1H), 7.10 (s, 1H), 4.88 (d,  $J=9\text{ Hz}$ , 1H), 3.62 (m, 1H), 3.25 (m, 1H), 3.00 (m, 3H), 2.78 (m, 1H), 20 2.48 (m, 2H), 2.25 (m, 1H), 1.50 (m, 3H), 1.26 (m, 2H).

### EXAMPLE 7

#### Step A :


25



- To a 500 ml round bottom flask equipped with a stirring bar, charge 10.0 g of (11*R*)-(8-chloro-3, 10-dibromo-6, 11-dihydro-5*H*-benzo [5,6] cyclohepta [1,2-*b*] pyridin-11-yl)-1-piperidine (S)-N-acetyl-L-phenylalanate, add 100 mL of toluene, 50 mL of 25% NaOH solution, and 100 mL of  $\text{H}_2\text{O}$ . Stir 30 minutes, add 1.0 g celite®, stir for an additional 5 minutes, then filter. Wash the celite® pad with 10 mL toluene. Separate the organic and aqueous layers and wash the organic layer with water (4 x 50
- 30


- 5 mL followed by 1 x 150 mL). Add 40 mL DMF, 0.199 g 1-hydroxybenzotriazole (HOBT), 3.19 g 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide•HCl (EDCI•HCl) and 4.0 g of 1-N-*tert*-butoxycarbonylpiperidiny-4-acetic acid and stir at room temperature until the reaction is complete (as judged by HPLC monitoring of the reaction). To the reaction mixture, add 50 mL of H<sub>2</sub>O and separate the organic and aqueous layers. Wash the organic layer with AcOH solution (0.1 mL AcOH/20 mL H<sub>2</sub>O), 1 x 40 mL H<sub>2</sub>O, NaOH solution (6.4 grams 24% NaOH/36 mL H<sub>2</sub>O), 3 x 40 mL H<sub>2</sub>O and then NaCl solution (3.9 grams/40 mL H<sub>2</sub>O). Concentrate the organic layer to a volume of about 60 mL and chromatograph the toluene solution using 22.5 grams SiO<sub>2</sub> (Davison Grade 62), eluting with 1:1 EtOAc/toluene and collecting in 50 mL fractions. Analyze each fraction by thin layer chromatography and combine all fractions containing the product. Concentrate the combined fractions to about 50 mL, add 100 mL toluene and concentrate to about 100 mL. Add 3.5 grams alumina (basic, Activity I), stir for 30 minutes, filter and wash the alumina cake with 10 mL toluene. Repeat alumina slurry until HPLC indicates acceptable quality product. Concentrate toluene layer to about 20 mL, add 30 mL EtOAc, 60 mL heptane and allow to slowly cool to room temperature. After the product has precipitated, cool to 0°C for one hour, collect the solid and wash with 30 mL 2:1 heptane/EtOAc. Dry the solid in a vacuum oven overnight to yield 7.98 g of product.

<sup>1</sup>H NMR: (CDCl<sub>3</sub>, δ): 8.42 (s, 1H), 7.53 (s, 1H), 7.50 (s, 1H), 7.10 - 7.20 (m, 6H), 6.36 (d, 1H, *J*=7 Hz), 4.94 (d, 1H, *J*=10 Hz), 4.48 (m, 1H), 3.52 (m, 1H), 3.24 (m, 2H), 3.12 (m, 3H), 2.98 (m, 1H), 2.82 (m, 1H), 2.53 (m, 2H), 2.32 (m, 1H), 1.98 (s, 3H), 1.78 (m, 1H), 1.56 (m, 1H), 1.40 (m, 1H).

5 **Step B:**

To a 250 mL round bottom flask equipped with a stirring bar, charge 7.07 g of the product from step A, above. Add 35 mL ethyl alcohol 2B, and stir. Cool the solution in an ice bath for 10 minutes, then add 42 mL of a 3 N HCl solution while maintaining the temperature below 25°C. Stir the reaction at room temperature until hydrolysis is complete (as judged by HPLC), typically 6 hours or longer. (If necessary, place reaction in a water bath, and stir at 50°C for about 30 minutes to complete the hydrolysis.) Concentrate in a rotavap to about 35 mL, add 17.5 mL 1-methyl-2-pyrrolidinone, then adjust to pH 9 by slowly adding 3 N NaOH over a period of about 30 minutes, while avoiding solid formation by adjusting the rate of addition of the 3N NaOH. Add 28.0 g of urea, place in an oil bath heated to about 110°C, stir at mild reflux overnight to form a solid. Cool to about 50°C, then adjust to pH 6 using 3 N HCl. Collect the solid material, wash with 140 mL H<sub>2</sub>O, and dry in a vacuum oven overnight to yield 5.434 g of product.


<sup>1</sup>H NMR: (CDCl<sub>3</sub>, δ): 8.38 (d, 1H, J=8 Hz), 7.48 (m, 1H), 7.43 (s, 1H), 7.07 (m, 1H), 4.82 (d, 1H, J=10 Hz), 4.54 (m, 1H), 4.00 (br s, 2H), 3.77 (m, 1H), 3.56 (m, 1H), 3.20 (m, 1H), 2.90 (m, 1H), 2.60 - 2.80 (m, 3H), 2.30 (m, 2H), 2.18 (m, 2H), 1.90 (m, 1H), 1.65 (m, 2H), 1.38 (s, 9H), 1.00 - 1.45 (m, 7H).

5 **Step C :**

To a 500 mL round bottom flask equipped with a stirring bar, charge with 5.14 g of material from step B, above. Add 5 mL THF and 250 mL CH<sub>2</sub>Cl<sub>2</sub>. Stir at room temperature for about 30 minutes to dissolve all material to obtain a solution. Add  
 10 2.57 g of SiO<sub>2</sub>, stir for 30 minutes, and then filter through a pad of celite. Wash with 15 mL of CH<sub>2</sub>Cl<sub>2</sub>, concentrate to about 50 mL, then add 100 mL THF and concentrate by distillation to 50 mL. Add 100 mL ethyl acetate and concentrate to 50 mL to form a white precipitate. Add 25 mL of ethyl acetate again, concentrate to about 50 mL, then cool to about 35°C. Filter, wash the solid with 15 mL cold ethyl acetate, and dry  
 15 in a vacuum oven overnight to obtain 4.1187 g of product.

<sup>1</sup>H NMR: (CDCl<sub>3</sub>, δ): 8.42 (s, 1H), 7.58 (d, 1H, *J*=8 Hz), 7.50 (s, 1H), 7.16 (s, 1H), 4.92 (d, 1H, *J*=9 Hz), 4.62 (br s, 3H), 3.92 (m, 3H), 3.62 (m, 1H), 3.26 (m, 1H), 3.00 (m, 1H), 2.82 (m, 1H), 2.40 (m, 2H), 2.22 (m, 2H), 2.04 (m, 1H), 1.78 (m, 2H), 1.08 - 1.58 (m, 6H).

20

**EXAMPLE 8**

25

Mix the tricyclic compound shown above (0.207 g), hydroquinine (0.202 g) and 4-mesyloxy N-Boc-piperidine (0.204 g) in toluene (20 x), stir at ambient temperature for 10 minutes, and cool to 0° C. Add 1 mL of lithium diisopropyl amide mono



- 5 (tetrahydrofuran) solution (1.5 M in cyclohexane) ("LDA") slowly, while maintaining the temperature below 10° C. Warm the resulting mixture to ambient temperature and stir for 2 hours. HPLC analysis gives 91.5% conversion and 68.5% ee.

10

**EXAMPLE 9**

Using the same procedure as Example 8, obtain the alkylated product (35% e.e.) substituting the following quinoline alcohol derivative for the hydroquinine used in Example 8:

15

**EXAMPLE 10**


20

Mix the tricyclic compound (5.0 g) shown above and 4-mesyl(1-[1,1-dimethylethoxy)carbonyl]-4-piperidinylacetyl)piperidine (6.3 g) in 125 mL toluene or anisole, heat to 40° C for 30 minutes to obtain a clear solution, and cool to ambient temperature. Add the solution to a reaction flask containing solid quinine (6.3 g).

- 5 Add 1.5 eq of a solution of lithium diisopropylamide mono(tetrahydrofuran) (1.5 M in cyclohexane) ("LDA solution") slowly, while maintaining the temperature below 10° C, until the mixture turns red. Add H<sub>2</sub>O (1.2 eq), stir for 10 minutes, and cool the reaction mixture below 5° C. Slowly add 1.2 eq of the LDA solution and warm the reaction mixture to 16 °C to 20 °C to obtain a clear solution. Add an additional 1.3 eq
- 10 of the LDA solution over a five hour period. Stir the resulting mixture at ambient temperature for 18 hours. Cool the reaction to 0 °C and quench the reaction mixture with 20 mL water. Stir at 0 °C for 4 h and filter the quinine. Wash the organic phase with 1 N HCl. Separate the organic phase and reduce the toluene solution (organic top layer) by vacuum distillation to a volume of 45 mL, add 120 mL EtOH, and
- 15 reduce by vacuum distillation down to a volume of 45 mL. Cool the solution in an ice bath for 10 minutes, then add 53 mL of a 3 N HCl solution while maintaining the temperature below 25 °C. Stir the reaction at room temperature until hydrolysis is complete (as judged by HPLC), typically 6 hours or longer. (If necessary, place reaction in a water bath, and stir at 50°C for about 30 minutes to complete the
- 20 hydrolysis.) Concentrate in a rotavap to about 40 mL, add 120 mL toluene and 3 N NaOH until the pH of the aqueous is 12. Separate the toluene phase and reduce the toluene solution (organic top layer) by vacuum distillation to a volume of 40 mL. Add 120 mL isopropanol, and reduce by vacuum distillation down to a volume of 40 mL. Add a solution of 3.6 grams N- $\alpha$ -(tert-butoxycarbonyl)-L-asparagine in 80 mL
- 25 isopropanol, and subject the mixture to vacuum distillation to reduce the volume down to 40 mL. Add 80 mL isopropyl acetate and heat at reflux for 3 h. Cool and stir for 1 hour at ambient temperature. Filter and wash the solid with 25 mL isopropyl acetate. Dry in a vacuum oven at a temperature of 55° C for 18 hours to give the desired salt (98 % ee). The solid salt is suspended in 100 mL of toluene, 50 mL of
- 30 25 % NaOH solution, and 100 mL of H<sub>2</sub>O. Stir 30 minutes, separate the organic and aqueous layers and extract the aqueous layer with toluene (2 x 10 mL). Extract the toluene solution with 25 mL 3N HCl solution. The resulting aqueous solution may be treated with NaOH, 1-methyl-2-pyrrolidinone, and urea according to the procedure in Example 7 Step B to form the final compound formed in Example 7 Step B. If
- 35 desired, other salts may be formed by replacing N- $\alpha$ -(tert-butoxycarbonyl)-L-asparagine in the foregoing method with Di-p-toluoyl-L-tartaric acid, N-(tert-

- 5 Butoxycarbonyl)-L-proline, (S)-(-)-2-Hydroxy-3,3-dimethylbutyric acid, or (1R)-(+)-Camphanic acid.

**EXAMPLE 11**



- 10 The following illustrates a batch preparation:

To a reactor charge 33 kg of quinine. In a separate reactor, charge 33 kg of the tricyclic compound shown above, 27.4 kg of 4-mesyl-N-Boc-piperidine, and 660 L toluene, heat to a temperature between 30° to 35°C while agitating until all solids are dissolved, and slowly cool the solution to a temperature between 20°C to 25°C. Add this solution to the first reactor containing the quinine and start agitating the mixture. Charge 165 L of toluene to the reaction mixture, and slowly charge 60.7 kg of lithium diisopropylamide mono(tetrahydrofuran) (1.5 M in cyclohexane) to the reaction mixture, while cooling the temperature to between 0°C to 5°C. Charge 1518 mL water into the reactor, while maintaining the temperature between 0°C to 5°C. While agitating, slowly charge 45.9 kg lithium diisopropylamide mono(tetrahydrofuran) (1.5 M in cyclohexane), while maintaining the batch temperature between 0°C to 8°C. Slowly heat the batch to a temperature of  $18 \pm 2^\circ\text{C}$ , and agitate for a period of about 30 minutes at this temperature. Over a period of about 2 to 3 hours, charge 59.4 kg lithium diisopropylamide mono(tetrahydrofuran) (1.5 M in cyclohexane), while maintaining the batch temperature between  $14 \pm 2^\circ\text{C}$ . Agitate for about 12 hours at a temperature between  $14 \pm 2^\circ\text{C}$  until the reaction is finished (confirm by HPLC). Charge 198 L of water to the batch and stir at a temperature between 0°C to 5°C for about 4 hours. Filter the batch and collect filtrate in a reactor. Wash the filter cake (recovered quinine) with 66 L of toluene followed by 66 L of water and combine the washings with filtrate in the reactor. Separate the lower aqueous phase from the organic phase. Wash the organic phase with 132 L of 7.6% aqueous sulfuric acid and

- 5    separate phases to remove the lower aqueous phase. Add 198 L of 15% aqueous sulfuric acid to the batch while maintaining the reactor temperature below 80°C. Heat the batch and distill solvents from the solution until the batch temperature reaches about 85°C and stop distillation and stir the reaction for about 4 hours at about 85°C. After cooling the batch to about 25 °C, add 83 L of 25% ammonium hydroxide
- 10    solution and agitate at a temperature between 20°C to 30°C. Allow the batch to settle into layers and remove the lower aqueous layer. Cool the batch to a temperature below 20°C. Concentrate the batch by vacuum distillation to a final volume of about 264 L. Cool the batch to a temperature below 20°C, charge 627 L of ethyl alcohol, and concentrate the batch by vacuum distillation to a final volume of about 264 L, to
- 15    remove toluene by solvent exchange. Cool the batch to a temperature between 20°C to 25°C. Add a solution of 19.8 kg N-acetyl-L-phenylalanine in 495 L ethyl alcohol, heat the batch to a temperature between 55°C to 60°C, while agitating for about 1 hour. Cool to a temperature of between 20°C to 25°C. Subject the batch to vacuum distillation to reduce it to a final volume of about 264 L. Cool the batch to a
- 20    temperature between 15°C to 20° C, filter to recover the crystallized salt and wash with 52 L of a 1:1 solution of ethyl alcohol and methyl t-butyl ether. The washed crystals are dried for at least 16 hours at a temperature between 50°C to 60°C to produce 48 kg (84.4 % molar yield) of product (101.4 % purity; 98.8 % ee).

25

While the present invention has been described in conjunction with the specific embodiments set forth above, many alternatives, modifications and variations thereof will be apparent to those of ordinary skill in the art. All such alternatives, modifications and variations are intended to fall within the spirit and scope of the


30    present invention.



5


We claim:

1. A process for preparing a compound of the formula:



- 10 wherein X¹, X², X³, X⁴, and X⁵ are independently selected from the group consisting of H, halo, alkyl, alkoxy, aryl, and aryloxy, and R is a protecting group, said process comprising:


treating a compound having the formula



15

wherein X¹, X², X³, X⁴, and X⁵ are as defined above, with the following, in any sequence:


- (a) a non-nucleophilic strong base;  
 (b) a chiral amino alcohol; and  
 20 (c) a compound having the formula



wherein L is a leaving group and R is as defined above.


- 5           2.       The process of claim 1, wherein  $X^2$  and  $X^4$  are H, and  $X^1$ ,  $X^3$  and  $X^5$  are halo; and wherein the chiral amino alcohol is a compound

(i) having the formula



- 10       wherein the dotted line represents an optional second bond and wherein  $R^1$  is selected from alkoxy, aryloxy, or  $NR^A R^B$ , wherein  $R^A$  and  $R^B$  are selected from alkyl or aryl,  $R^1$  being optionally substituted by one or more alkoxy groups, or

(ii) having the formula




- 15       wherein  $R^2$  is a phenyl group optionally substituted by 1 to 5 substituents independently selected from the group consisting of alkyl and alkoxy.

3.       The process of claim 2, wherein  $X^1$  is Br,  $X^3$  is Cl, and  $X^5$  is Br.


4.       The process of claim 3, wherein at least one of the treatments with the non-nucleophilic strong base, the chiral amino alcohol, or the compound of formula  
20 (V) occurs in the presence of water or a  $C_1$ - $C_3$  alcohol.

5.       The process of claim 4, wherein at least one of the treatments with the non-nucleophilic strong base, the chiral amino alcohol, or the compound of formula (V) occurs in the presence of water, and the non-nucleophilic strong base is lithium diisopropylamide.

- 25       6.       The process of claim 5, wherein the chiral amino alcohol is selected from the group consisting of quinine, hydroquinine,



5






7. The process of claim 6, wherein the chiral amino alcohol is quinine.


8. The process of claim 7, wherein the leaving group, L, is selected from the group consisting of sulfonates, phosphates, benzoates, and halo.

9. The process of claim 8, wherein the leaving group is mesylate or  
10 tosylate.


10. The process of claim 9, wherein R is selected from the group consisting of tert-butoxycarbonyl,




15



- 10 11. The process of claim 10, wherein R is tert-butoxycarbonyl










12. The process of claim 6, wherein the chiral amino alcohol is





13. The process of claim 12, wherein the leaving group, L, is selected from  
15 the group consisting of sulfonates, phosphates, benzoates, and halo.


5            14.    The process of claim 13, wherein the leaving group is mesylate or tosylate.

15.    The process of claim 14, wherein R is selected from the group consisting of tert-butoxycarbonyl,






16. The process of claim 15, wherein R is tert-butoxycarbonyl




17. A process for preparing a compound having the formula



10 wherein  $X^1$ ,  $X^2$ ,  $X^3$ ,  $X^4$ , and  $X^5$  are independently selected from the group consisting of H, halo, alkyl, alkoxy, aryl, and aryloxy, and R is a protecting group, said process comprising:


(a) reacting a compound having the formula



15


wherein  $X^1$ ,  $X^2$ ,  $X^3$ ,  $X^4$ , and  $X^5$  are as defined above, with a non-nucleophilic strong base in the presence of a chiral amino alcohol to form a complex;

- 5 (b) reacting the complex formed in step (a) with a compound having the formula




wherein L is a leaving group and R is as defined above.

18. The process of claim 17, wherein said process is carried out in the  
 10 presence of water, and wherein said chiral amino alcohol is selected from  
 (i) a compound having the formula



- wherein the dotted line represents an optional second bond and wherein R¹ is selected  
 15 from alkoxy, aryloxy, or NR<sup>A</sup>R<sup>B</sup>, wherein R<sup>A</sup> and R<sup>B</sup> are selected from alkyl or aryl,  
 R¹ being optionally substituted by one or more alkoxy groups, or


(ii) a compound having the formula



- wherein R² is a phenyl group optionally substituted by 1 to 5 substituents  
 20 independently selected from the group consisting of alkyl and alkoxy.

19. The process of claim 18, wherein X² and X⁴ are H, X¹ is Br, X³ is Cl,  
 and X⁵ is Br, the non-nucleophilic strong base is lithium diisopropylamide, the

- 5 leaving group, L, is mesylate, R is tert-butoxycarbonyl, and the chiral amino alcohol



is selected from quinine or

20. The process of claim 18, wherein

(a) 1.2 to 1.4 eq. of the non-nucleophilic strong base are added to a solution containing:

- 10 (i) the compound of formula (II),  
(ii) 1.1 to 1.3 eq. of the compound of formula (V), and  
(iii) 1.2 to 1.4 eq. of the chiral amino alcohol,

while maintaining the temperature at 10° C to 30° C;

- (b) the mixture from step (a) is cooled to 0° C to 10° C, and 0.8 to 1.2  
15 eq. of water are added;

(c) an additional 0.9 to 1.1 eq. of the non-nucleophilic strong base are added to the mixture from step (b) while maintaining the temperature at 0° C to 10° C;

- (d) the temperature of the mixture from step (c) is raised to 14° C to  
20 18° C, and an additional 1.1 to 1.3 eq. of the non-nucleophilic strong base are added while maintaining the temperature at 14° C to 18° C; and

(e) the chiral amino alcohol is recovered.



# INTERNATIONAL SEARCH REPORT

International Application No  
PCT/US 99/26009

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07D401/04 C07B53/00 //(C07D401/04, 221:00, 211:00)

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07D C07B

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	S.B. HEATON ET AL.: TETRAHEDRON LETTERS, vol. 33, no. 13, 1992, pages 1693-1696, XP002130990 OXFORD GB the whole document	1-20
A	F.J. VILLANI ET AL.: JOURNAL OF MEDICINAL CHEMISTRY, vol. 15, no. 7, 1972, pages 750-754, XP000578364 WASHINGTON US scheme I	1-20

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

### \* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

18 February 2000

Date of mailing of the international search report

09/03/2000

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Frelon, D

# INTERNATIONAL SEARCH REPORT

International Application No  
PCT/US 99/26009

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	CHEMICAL ABSTRACTS, vol. 121, no. 7, 15 August 1994 (1994-08-15) Columbus, Ohio, US; abstract no. 82181, XP002130992 abstract & W.S. FABER ET AL.: TETRAHEDRON, vol. 50, no. 16, 1994, pages 4775-4794, OXFORD GB	1-20
A	CHEMICAL ABSTRACTS, vol. 116, no. 19, 11 May 1992 (1992-05-11) Columbus, Ohio, US; abstract no. 194813, XP002130993 abstract & S. AHMAD ET AL.: JOURNAL OF MEDICINAL CHEMISTRY, vol. 35, no. 8, 1992, pages 1410-1417, WASHINGTON US	1-20
A	CHEMICAL ABSTRACTS, vol. 95, no. 15, 12 October 1981 (1981-10-12) Columbus, Ohio, US; abstract no. 128976, XP002130994 abstract & T. KAJIWARA ET AL.: AGRIC. BIOL. CHEM., vol. 45, no. 6, 1981, pages 1461-1466,	1-20
A	CHEMICAL ABSTRACTS, vol. 82, no. 17, 28 April 1975 (1975-04-28) Columbus, Ohio, US; abstract no. 111993, XP002130995 abstract & H. GUSTAFSSON ET AL.: ACTA CHEM. SCAND. SER. B, vol. B28, no. 9, 1974, pages 1069-1073,	1-20
A	WO 93 21176 A (WARNER LAMBERT CO) 28 October 1993 (1993-10-28) page 28 -page 29	1-20
A	S. GAUTHIER ET AL.: JOURNAL OF MEDICINAL CHEMISTRY, vol. 40, 1997, pages 2117-2122, XP002130991 WASHINGTON US scheme 2	1-20

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 99/26009

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9321176 A	28-10-1993	US 5264577 A	23-11-1993
		AU 672209 B	26-09-1996
		AU 4290393 A	18-11-1993
		CZ 9402568 A	12-04-1995
		EP 0637305 A	08-02-1995
		FI 944906 A	19-10-1994
		JP 7506100 T	06-07-1995
		MX 9302327 A	01-10-1993
		NO 944014 A	21-12-1994
		NZ 252854 A	27-11-1995
		SK 128694 A	10-05-1995
		US 5380925 A	10-01-1995
		US 5449778 A	12-09-1995